Physics Keynote Sessions
Adaptive Proton Therapy: Friday 4 June 2021, 3:45pm UTC / GMT
Dr. Francesca Albertini
Center for Proton Therapy at the Paul Scherrer Institute (PSI)
Completed her bachelor degree in Physic and the Master of Science (MSc) in Nuclear Physic at the University of Milano in 2002. During the Post-Graduated study as Medical Physics she started the trainee as clinical medical physicist in nuclear medicine in Milano, at the Istituto Nazionale dei Tumori of Milano. In 2004 she moved to Switzerland, where she completed her trainee in radiotherapy at the Center for Proton Therapy at the Paul Scherrer Institute (PSI). She was lucky enough to have the possibility to combine a PhD on evaluating and estimating the effect of uncertainties for actively scanned proton therapy while working as clinical medical physicist at PSI. Since February 2011, when she obtained her PhD in Physic at the ETH (Swiss Federal Institute of Technology) Zurich, she coordinated the advancement of the in-house developed treatment planning clinically used at PSI. As such, research activities have been concentrated around advanced treatment planning approaches, proton therapy workflow and QA. In the past 6 years, her main interest focuses on the on-line adaptive proton therapy workflow. Currently, she is the scientific coordinator of the European H2020-MSCA-ITN RAPTOR (Real-time Adaptive Particle Therapy Of canceR) consortium aiming to work on developments required for real-time adaptive proton therapy. She is the author or co-author of over 45 peer reviewed papers and articles and have contributed to 4 scientific books.
Advanced Therapies: SPARC: Monday 7 June 2021, 1:30pm UTC / GMT
Dr. Rohan Deraniyagala MD
Medical Director of Beaumont PTC
Dr. Rohan Deraniyagala received his bachelor’s degree in computer engineering at the University of Michigan in Ann Arbor, MI. He earned his medical degree from Wayne State University in Deroit, MI. Dr. Deraniyagala completed his residency training in radiation oncology at the University of Florida in Gainesville, FL and completed a proton therapy fellowship at the University of Florida Health Proton Therapy Center in Jacksonville, FL. In 2016, he joined William Beuamont Hospital in Royal MI as an assistant professor in radiation oncology. Dr. Deraniyagala became service chief for head and neck radiation oncology as well as pediatrics. He was then appointed as clinical director of the Beaumont Proton Therapy center. His research interests include adaptive head neck radiation, proton arc therapy and artificial intelligence. He has multiple peer-reviewed papers and conference abstracts. He is certified by the American Board of Radiology in radiation oncology.
Dr. Xuanfeng Ding
Lead Medical Physicist, Proton Beam Therapy at William Beaumont Health System
Dr. Ding received his Ph.D. in Physics from Wake Forest University, Winston-Salem in 2012, and received his residency training at the University of Pennsylvania, Philadelphia. Later, he commissioned the first compact PBS proton system, IBA ProteusONE in Willis-knighton Cancer Center. In the summer of 2015, he joined William Beaumont Hospital, Royal Oak, MI, as the lead proton physicist and assistant professor to build the proton clinical, research and education program from the scratch. Dr. Ding’s research interests include proton arc therapy, adaptive therapy, and motion management. In his early career, he has been granted multiple extramural research fundings, patents and published over 30 peer-reviewed papers, 1 book chapter and over hundreds of conference abstracts. He is certified by the American Board of Radiology in Therapeutic Radiologic Physics. He also served as the president of the Great Lakes Chapter AAPM in 2020 and committee in several AAPM Task Groups as well .
Clinics Keynote Sessions
Immuno - Therapy: Saturday 5 June 2021, 2:30pm UTC / GMT
Dr. Sean Park
Mayo Clinic Rochester
Sean S. Park, M.D., Ph.D. is an Associate Professor in Radiation Oncology, College of Medicine at Mayo Clinic Rochester. Dr. Park completed his undergraduate studies Magna Cum Laude at the University of California at San Diego and his M.D./Ph.D. in immunology at the Chicago Medical School with Alpha Omega Alpha distinction. He was a chief resident at William Beaumont Hospital before joining the faculty at Mayo Clinic.
Dr. Park’s clinical expertise includes HDR brachytherapy, stereotactic body radiotherapy, image-guided radiotherapy, and intensity-modulated proton therapy. His research focus is improving clinical outcomes in patients with metastatic cancers. Dr. Park recently completed an NCI-funded phase II study in oligometastatic castration-resistant prostate cancer patients identified on 11C-choline PET/CT treated with SBRT. His complementary translational research focuses on the immune-induction effects of radiotherapy to develop novel treatments through a multidisciplinary team approach by combining the latest technology in radiotherapy – including proton therapy -- with immunotherapy to improve outcomes in metastatic cancer patients while safely minimizing side effects. Dr. Park also serves as co-Chair of Radiation Oncology Safety and Incident Learning System to identify potentially harmful incidents and to implement effective and efficient safety barriers.
Hepatocellular Carcinoma: Monday 7 June 2021, 11:00am UTC / GMT
Dr. Jason Molitoris
University of Maryland School of Medicine
Jason Molitoris is an Assistant Professor in the University of Maryland School of Medicine in Baltimore MD, USA. He is a board certified radiation oncologist practicing at the University of Maryland Medical Center and the Maryland Proton Treatment Center, where he completed his training. He is a co-chair of the PTCOG GI subcommittee. Active areas of research interest include use of advanced modalities of treatment including Proton Therapy, Hyperthermia and Brachytherapy.
Biology Keynote Sessions
Overview of the NASA program, their research portfolio, and the overlap with medicine: Sunday 6 June 2021, 2:30pm UTC / GMT
Dr. Robin Elgart
Space Radiation Element Scientist
Space Radiation Element Scientist
NASA Human Research Program
Dr. Elgart received her B.S. in Microbiology from the University of California at Santa Barbara and her Ph.D. in Biomedical Physics from the University of California at Los Angeles in the laboratory of Dr. Keisuke Iwamoto. Her dissertation focused on characterizing the DNA damage response following low-dose radiological exams in patient samples. Robin has over fifteen years of diverse research experience across multiple life-science disciplines including medical physics and radiation biology. Before joining HRP as the Space Radiation Element Scientist in April 2020, Robin served as a subject matter expert specializing in space radiation health risks for the NASA Space Radiation Analysis Group as well as a Space Environment Officer for Mission Control Center – Houston. As the Space Radiation Element Scientist, Robin’s primary objective is to develop and execute a robust applied research strategy to meet the agency’s goal to safely put the first woman on the Moon and the first humans on Mars.
Advanced Therapies: Mini Beams / MBRT: Saturday 5 June 2021, 10:15am UTC / GMT
Dr. Yolanda Prezado
New Approaches in Radiotherapy (NARA)- Institut Curie
Dr. Yolanda Prezado is the head of the interdisciplinary team “New Approaches in Radiotherapy (NARA)” based at Institut Curie (Orsay, France). The main research avenue of the NARA team is the conception and development of innovative radiotherapy techniques based on the spatial fractionation of the dose. In 2018 she was awarded an ERC consolidator grant to fund what is currently the team’s flagship project: Proton Minibeam Radiation Therapy.
After some years working as a clinical medical physicist, she became beamline scientist at the Biomedical Beamline of the European Synchrotron Radiation facility (Grenoble, France). There, she stayed from 2007 to 2011 and started exploring the limits of spatial fractionation of the dose with techniques like Microbeam and Minibeam Radiation Therapy. From 2011 onwards, she is a tenured scientist at French National Research Centre (CNRS), based at Campus of Orsay, where she pioneered the combination of spatial fractionated radiotherapy and charged particles. In 2019, she moved to Institut Curie to lead a SIRIC (“comprehensive research against cancer”) labelled new group in radiobiology.
She has acted as Chair of Science Committee of European Federation of Medical Physics (2019-2020). She is currently the vice-spokesperson of the International Biophysics Collaboration.
Facility Set Up Issues & PTCOG 59 Exhibition Opening:
Saturday 5 June 2021, 11:15am UTC / GMT
Vice President, Cincinnati Children’s Innovation Ventures & Executive Director, Cincinnati Children’s Proton Therapy Center
Abram S. Gordon, Vice President, Cincinnati Children’s Innovation Ventures, Executive Director, Cincinnati Children’s Proton Therapy Center. A proven leader with experience in the biomedical/life sciences/digital arenas, with a focus on corporate law, healthcare, and commercialization, he is well-versed in the Greater Cincinnati Innovation ecosystem.
Gordon has managed the Cincinnati Children’s Proton Therapy Center since June 2014, shortly after construction on the Center commenced. He oversaw the construction of the Center, the integration of the Center into the Hospital’s operations and had led its operations since it began treating patients in October, 2016. The Center recently treated the first patient on a clinical trial using a FLASH treatment.
Gordon also oversees the hospital’s technology transfer and commercialization department. His group concentrates on accelerating discoveries, in particular, those with the greatest potential to become products that improve and save lives. Collaborating with industry, venture capital, foundations, and government sponsored programs, Gordon and his team ensure scientific and technical innovations developed at Cincinnati Children’s achieve maximum value and impact, not only at Cincinnati Children’s, but around the world by building a bridge between the discoveries and the new or existing companies prepared to bring those technologies to fruition.
Gordon is the Board Chair of National Association of Proton Therapy. He also actively serves as a Member of the Board of Directors of: Kurome, Inc; IncludeHealth, Inc.; BioOhio; and CincyTech, as well as a Board Observer on Bexion, Inc., and Aruvant Sciences.
He earned his undergraduate and Juris Doctorate degrees from Boston University.
Dr. Prathap C. Reddy
Founding Chairman, Apollo Group Hospitals
A compassionate humanitarian, dedicated to bringing world-class healthcare within the economic and geographic reach of millions of patients' best describes Dr. Prathap C Reddy, Founder Chairman of the Apollo Hospitals Group. Dr. Reddy received his medical degree from the Stanley Medical College in Chennai and later trained as a Cardiologist in the UK and USA. He did his Fellowship from the Massachusetts General Hospital, Boston and went on to head several research programs at the Missouri State Chest Hospital, USA where he worked for several years before returning to India in 1971, at the behest of his father. This act of leading by example in reversing the brain drain eventually became an agenda with Apollo Hospitals, India's first corporate hospital that heralded the country's burgeoning private healthcare industry. The dream of making world-class medical available in India spurred him to set up the Apollo Hospitals in Chennai in 1983 at a time when private healthcare institutions were virtually unknown in our country. The new hospital attracted the best medical talent, including eminent non-resident Indian doctors from hospitals in the US and UK. Starting from a 150-bedded Hospital in 1983, the Group has since continuously excelled and maintained leadership in medical innovation, clinical services and cutting edge research. With a network of over 10,000 beds across 64 hospitals at culturally diverse locations in India and overseas, over 4000 top class clinicians and total employee strength of more than 65,000 professionals, the Apollo Hospitals Group is one of the largest hospital groups in the world, being consistently ranked amongst the best hospitals for advanced medical services. These hospitals have served over 42 million patients from 120 countries, with seven of them having the prestigious JCI accreditation. Dr Reddy's pioneering success includes the initiation of a change towards preventive care, by pushing for a new standard in assessing and diagnosing India's health to fight the triple terrors of diabetes, heart diseases and cancer through preventive health checks. Telemedicine, as in the world's first V-SAT enabled village, and health insurance like the Aragonda Re. 1/day scheme, were other successful pilots. His mantra has been to identify the need of India, and fill the lacuna using a stretch of innovation, technology and commitment. Dr Reddy has undertaken pioneering work in bringing about institutional changes in the private healthcare infrastructure by establishing Apollo Institutes for post graduate Medical and Nursing Education, Hospital Administration, Physiotherapy, Clinical Research and a large number of Paramedical Programs. With the setting up of the Apollo Telemedicine Networking Foundation, Health Super Hiway, Apollo Munich Insurance Co and the Apollo Reach Hospitals, he helped establish a modern healthcare network through both in-house and outreach services, reaching out to millions of people. As the Chairman of the CII National Healthcare Committee since 2006, Dr Reddy constituted sub-committees for drawing up standards for accreditation of Indian Hospitals for the very first time in the country. Ever since, the committees have done commendable work in the areas of medical value travel and medical code of ethics. One of the areas of significant impact has been in the area of budget recommendations to the Government and development of Health Insurance. As the Chairman of the CII Health Council since 2010, Dr Reddy is Advisor to its committees on Healthcare, Health Insurance, Public Health and Pharma. As Chairman of the CII National Council on Public Health since 2011, with a view to supplementing Government's efforts in the area of public health, Dr Reddy is working on expanding their coverage through efficiency and quality interventions, by leveraging appropriate partnerships with the private sector as well as civil society institutions. Dr Reddy was awarded the Padma Bhushan in 1991 for his contribution to the emergence of the private healthcare sector and his role in bringing about several regulatory changes relating to licensing, import restrictions, organ transplantation, etc. He received a number of esteemed awards and recognitions such as Mother St Teresa's 'Citizen of the Year Award', recognition in Harvard School publications for pioneering efforts in healthcare, 'Life Time Achievement Award' by Hospimedica International, the 'Asia Pacific Bio Business Leadership Award' by the University of Southern California, Modern Medicare Excellence Award by the ICICI Group for outstanding achievements in the healthcare industry and numerous others. Dr Reddy is also a recipient of the Lifetime Achievement award from Rotary International. In addition he has received Lifetime Achievement awards from the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Association of Surgeons of India. He was also awarded the Alexandria – Frost & Sullivan 2010 India Excellence Lifetime Achievement Award. Marking a new beginning, the All India Management Association conferred the AIMA Lifetime Contribution Award upon Dr. Prathap C Reddy recently. The Government of India honoured the pioneering spirit of the Apollo Hospitals Group with the release of a commemorative Postage Stamp. Dr Prathap C Reddy was conferred with second highest civilian award, the 'Padma Vibhushan' in March 2010. This unequalled commendation from the Government of India is an acknowledgement of his untiring pursuit for excellence in healthcare as Apollo strives towards touching a billion lives. Under Dr Reddy's leadership, the Apollo Group has undertaken philanthropic work through 'Save a Child's Heart Initiative' (SACHi), the CURE Foundation for cancer care, the Indian Head Injury Foundation (IHIF), 'Distance Healthcare Advancement' (DISHA), and many others that have touched the lives of several hundred thousand children, differently-abled people, cancer and brain trauma patients.